AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 3 - (NewsRx.com & NewsRx.net) -- Novirio Pharmaceuticals, Ltd., has announced that the Institut Pasteur in Paris, France, has set up a program to evaluate Novirio's extensive library of compounds for antiviral activity against several hemorrhagic fever viruses (HFV) including Ebola, Marburg, and Lassa, some of the deadliest viruses known to man.
Novirio Pharmaceuticals has been successful in selecting multiple potent antiviral drug candidates from its library of compounds for application against hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV/AIDS. Among these programs, Novirio has advanced two drug candidates for the treatment of HBV into phase II clinical testing. The HFV research program is intended to combine the resources of the Institut Pasteur, one of the world's leading infectious disease research centers, with the unique drug discovery approach of Novirio in an effort to address an urgent medical need.
"Novirio is pleased to partner with the Institut Pasteur to advance medical discoveries in the area of HFV. The potential threat of an outbreak of one of these deadly viruses is of immense importance as there are no vaccines or effective treatments currently available," commented ...
Source: HighBeam Research, Institut Pasteur enters agreement to research treatments for...